TY - JOUR
T1 - Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis [Podcast]
AU - Merola, Joseph F.
AU - Amin, Ahmad Z.
N1 - Publisher Copyright:
© 2024 Boehringer Ingelheim Pharmaceutica.
PY - 2024
Y1 - 2024
N2 - Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with the appearance of painful skin erythema, followed by the widespread eruption of sterile pustules. Acute GPP (called a flare) is often accompanied by systemic symptoms, including high fever, pain in skin lesions, malaise, and fatigue. Approximately half of GPP flares require hospitalization, with an average inpatient duration of 10–14 days. GPP prevalence estimates range from approximately 2–124 cases per million persons, with a female predominance. The most common age of onset of GPP is 40–60 years, although cases have been described in younger adults and children. GPP affects every aspect of patients’ lives and has a high physical and psycho-social impact. Recent research on the interleukin-36 pathway associated with GPP led to the development of a GPP-specific treatment, spesolimab, which was approved by the US FDA in September 2022. This podcast explores the clinical presentation, disease course, and burden of disease in GPP, including differential diagnosis and common triggers of an acute flare.
AB - Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with the appearance of painful skin erythema, followed by the widespread eruption of sterile pustules. Acute GPP (called a flare) is often accompanied by systemic symptoms, including high fever, pain in skin lesions, malaise, and fatigue. Approximately half of GPP flares require hospitalization, with an average inpatient duration of 10–14 days. GPP prevalence estimates range from approximately 2–124 cases per million persons, with a female predominance. The most common age of onset of GPP is 40–60 years, although cases have been described in younger adults and children. GPP affects every aspect of patients’ lives and has a high physical and psycho-social impact. Recent research on the interleukin-36 pathway associated with GPP led to the development of a GPP-specific treatment, spesolimab, which was approved by the US FDA in September 2022. This podcast explores the clinical presentation, disease course, and burden of disease in GPP, including differential diagnosis and common triggers of an acute flare.
KW - clinical presentation
KW - diagnosis
KW - disease burden
KW - generalized pustular psoriasis
KW - interleukin-36 pathway
UR - http://www.scopus.com/inward/record.url?scp=85186942306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186942306&partnerID=8YFLogxK
U2 - 10.2147/CCID.S444221
DO - 10.2147/CCID.S444221
M3 - Comment/debate
C2 - 38482176
AN - SCOPUS:85186942306
SN - 1178-7015
VL - 17
SP - 539
EP - 545
JO - Clinical, Cosmetic and Investigational Dermatology
JF - Clinical, Cosmetic and Investigational Dermatology
ER -